News

The 20th-century advance in American pharmaceutical science was driven by a cohort of devoted researchers working with ambitious drug companies.

Tempus AI could capture a lucrative slice of Moderna and Merck’s personalized cancer therapy business, with Personalis at the center of the bet.

Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

August was good to U.S. stock investors. All three major U.S. indexes are on track to finish the month in the green—something that has happened since May. The tech-focused Nasdaq is leading the way, up about 4.

For drugmakers, a clock starts before a drug is even approved: Patents run out, lower-priced copycats flood in and sales collapse. The pharma industry is entering its biggest wave of patent expirations in decades. The world’s bestselling drug in 2025, Merck’s cancer immunotherapy Keytruda, loses U.S. patent protection in 2028, and nearly every pharma company has at least one blockbuster drug that will go off patent in the next five years.

Over the past 12 months, the State Street SPDR S&P Biotech ETF is up around 85% versus roughly 20% for the S&P 500. Last week added an exclamation point: Moderna more than doubled in a single session after its mRNA cancer vaccine, developed with Merck, cleared a late-stage melanoma trial. For decades, U.S. and other Western companies enjoyed something close to a monopoly on cutting-edge science.

Gain insight on Moderna, Novo Nordisk and more in the latest Market Talks covering the Health Care sector.

Merck added billions in a single day after its Moderna-partnered cancer vaccine cleared a major hurdle.

Moderna has always been a stock driven by narrative extremes. During the pandemic, it traded as if mRNA would transform medicine overnight, with its market capitalization peaking near $200 billion. Shares exploded 177% in a single session on Wednesday—the largest one-day surge for an S&P 500 company in over two decades—after Moderna and partner Merck reported successful late-stage trial results for their personalized mRNA melanoma vaccine.

Scientists are on the cusp of fulfilling a decades-long quest: to use vaccines to teach the immune system to spot and destroy cancer cells. News that an mRNA cancer vaccine developed by Merck & Co. and Moderna Inc. kept melanoma from returning in a large, late-stage trial marks a critical next chapter for a technology beleaguered by post-pandemic political backlash and years of false starts before then. Bloomberg Opinion Columnist Lisa Jarvis writes "Moderna and Merck's Cancer Vaccine Is a Marvel."

The stock market still looks basically healthy, but the bond market is starting to show signs of stress.

Investing.com -- A historic single-day move in biotech dominated the week, while a Treasury liquidity announcement impacted crypto and metals. Two well-known consumer names went in opposite directions on earnings.

The market rally flashed some bearish signals. Moderna skyrocketed on a cancer vaccine while gold and bitcoin jumped. Walmart dived.

Find insight on Moderna, Merck KGaA, Novonesis and more in the latest Market Talks covering the health care sector.

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.5% and the actively tr

Dow Jones futures: Crude oil continues to climb while bitcoin jumped again amid a weak dollar. Walmart earnings are in focus.

By Mike Dolan Aug 20 (Reuters) - What matters in U.S. and global markets today By Mike Dolan, Editor-at-Large, Finance and Markets Buybacks to the rescue? The surprising move by the U.S.

(Updates with market moves at the end of the day, and other changes, if any.) Wall Street's main

Drug company stocks soared following news that Moderna and Merck’s experimental mRNA-based cancer vaccine succeeded in a late-stage trial at preventing melanoma from returning or spreading. The S&P health-care sector is on track for an all-time closing high, as is Merck, according to data that goes back to 1972. As of Wednesday afternoon, Moderna’s stock had more than doubled, something that a member of the S&P 500 hasn't done in a single day since 2008, according to Dow Jones Market Data.

(Updates with latest market prices and developments.) US benchmark equity indexes were higher int

A personalized vaccine developed by Moderna Inc. and Merck & Co. reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technology. Bloomberg's Sam Fazeli joins to discuss.

By Christy Santhosh and Shashwat Chauhan Aug 19 (Reuters) - Moderna shares more than doubled on Wednesday, adding about $30 billion to its market value, after promising late-stage data on its

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock

An experimental mRNA-based vaccine succeeded in preventing cancer from coming back or spreading in a study of high-risk melanoma patients, Moderna and its partner Merck said. Shares in Moderna jumped about 10% premarket, while Merck also climbed around 6%.

Result in high-risk patients validates decades of research into mRNA-based therapeutic cancer vaccines.

Pharmaceutical chiefs are always hunting for drugs to replace expiring blockbusters. But shopping while hungry can lead to expensive mistakes.

Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to make a move before pivotal trial data arrives.

AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.

With CPI dropping at 8:30 AM and the Strait of Hormuz near shutdown, Wall Street faces a pivotal morning that could swing stocks sharply in either direction, and analysts at Deutsche Bank, Oppenheimer, Berenberg, and others are already repositioning ahead of the numbers.

Oncology and animal health drove $16.6B revenue growth amid upcoming patent expirations.